Skip to content

FLO for Discogenic Pain

FLO Injection for Discogenic Pain

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03644251
Enrollment
3
Registered
2018-08-23
Start date
2018-08-13
Completion date
2019-03-04
Last updated
2019-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Discogenic Back Pain

Brief summary

Discogenic pain is pain originating from a damaged vertebral disc and be caused by inflammation, dehydration of the nucleus pulposus, decreased disc height, annular tears and impaired mechanical function of the disc.Non-operative treatment may include traction, steroid therapy, methylene blue injection and ablative therapy. However, there are few high quality studies evaluating these treatments for reducing discogenic low back pain and most clinical trials failed to detect significant differences between treatments and placebo therapies. Hence, there remains an unmet clinical need.

Interventions

OTHERamniotic and umbilical cord matrix

Cryopreserved human amniotic and umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability.

Sponsors

BioTissue Holdings, Inc
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* subject (male or female) is at least 18 to 70 years of age * diagnosed with single level discogenic back pain confirmed by MRI and positive discography per Spine Interventional Society Guidelines * Diagnosis of disc degeneration with Pfirrmann score of 1-3 * Subject has failed at least six months of conservative care * Subject is symptomatic with axial lower back pain greater than lower limb pain at the intensity of \>6/10 concordant or partially concordant * The subject is able to comply with all post-operative standard of care and follow instructions.

Exclusion criteria

* Subjects has significant disc protrusion, severe lumbar spinal stenosis, spine tumor, severe disc degeneration, or Sacroiliac (SI) joint syndrome * Subject had previous surgery at the disc level * Patient has previously received injection of FLO within 3 months of screening * The subject is unable to comply with follow-up or not appropriate for inclusion based on investigator decision

Design outcomes

Primary

MeasureTime frameDescription
Change in patient back pain determined by visual analog scale3 months0 to 100mm, 100mm worst pain

Secondary

MeasureTime frameDescription
Change in quality of life determined by SF-363 and 6 monthsShort FormHealth Survey to evaluate quality of life across eight scales
Change in patient back pain determined by visual analog scale6 months0 to 100mm, 100mm worst pain
Change in Oswestry Disability Index3 and 6 months0 to 50, higher the percentile, the worse the perceived lower back pain

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026